Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. Giles FJ, et al. Among authors: borthakur g. Br J Haematol. 2007 Feb;136(4):624-7. doi: 10.1111/j.1365-2141.2006.06476.x. Br J Haematol. 2007. PMID: 17223919 Free article.
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Tam CS, et al. Among authors: borthakur g. Blood. 2008 Aug 1;112(3):516-8. doi: 10.1182/blood-2008-02-141580. Epub 2008 May 20. Blood. 2008. PMID: 18492956 Free PMC article. Clinical Trial.
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. Faderl S, et al. Among authors: borthakur g. Blood. 2008 Sep 1;112(5):1638-45. doi: 10.1182/blood-2007-11-124602. Epub 2008 Jun 18. Blood. 2008. PMID: 18565853 Free PMC article. Clinical Trial.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Fava C, et al. Among authors: borthakur g. Blood. 2009 May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12. Blood. 2009. PMID: 19282457 Free PMC article. Clinical Trial.
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Quintás-Cardama A, et al. Among authors: borthakur g. Blood. 2009 Jun 18;113(25):6315-21. doi: 10.1182/blood-2008-07-166694. Epub 2009 Apr 15. Blood. 2009. PMID: 19369233 Free PMC article.
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Jabbour E, et al. Among authors: borthakur g. Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30. Blood. 2009. PMID: 19567878 Free PMC article.
505 results